Opus Genetics (NASDAQ:IRD) Insider Ashwath Jayagopal Sells 3,719 Shares

Opus Genetics, Inc. (NASDAQ:IRD) insider Ashwath Jayagopal sold 3,719 shares of Opus Genetics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $5.12, for a total transaction of $19,041.28. Following the completion of the transaction, the insider directly owned 516,775 shares in the company, valued at $2,645,888. The trade was a 0.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Opus Genetics Stock Down 4.0%

NASDAQ:IRD traded down $0.19 during trading hours on Thursday, reaching $4.48. 327,179 shares of the company’s stock were exchanged, compared to its average volume of 993,493. The firm has a market capitalization of $318.40 million, a price-to-earnings ratio of -5.41 and a beta of 0.45. The company has a 50-day moving average of $3.35 and a 200 day moving average of $2.41. Opus Genetics, Inc. has a 1-year low of $0.65 and a 1-year high of $5.30.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Piper Sandler initiated coverage on Opus Genetics in a report on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. B. Riley Financial started coverage on Opus Genetics in a report on Wednesday, December 10th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, BTIG Research upped their price target on Opus Genetics from $7.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IRD. Balyasny Asset Management L.P. acquired a new stake in Opus Genetics in the fourth quarter valued at about $5,463,000. BIOS Capital Management LP boosted its holdings in Opus Genetics by 270.1% in the 2nd quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock valued at $3,462,000 after purchasing an additional 2,688,180 shares in the last quarter. Millennium Management LLC acquired a new position in Opus Genetics during the 4th quarter worth approximately $4,025,000. Nantahala Capital Management LLC increased its position in Opus Genetics by 42.9% during the 4th quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock worth $9,610,000 after purchasing an additional 1,435,407 shares during the period. Finally, Mink Brook Asset Management LLC raised its stake in shares of Opus Genetics by 34.5% during the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock worth $3,348,000 after buying an additional 427,684 shares in the last quarter. 14.97% of the stock is currently owned by institutional investors and hedge funds.

More Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple analysts initiated/raised coverage with bullish ratings and higher price targets (Oppenheimer started coverage with an “outperform” and $10 target; Wedbush and BTIG recently raised targets and maintained buy/outperform views), giving the stock upside potential versus current levels. Article Title
• Neutral Sentiment: Institutional ownership movements show recent inflows from several funds (BIOS Capital, Voss Capital, Wells Fargo, State Street increased positions), which may support longer-term demand but have unclear timing impact on the share price. Article Title
• Neutral Sentiment: Liquidity and technicals: today’s volume is below the stock’s average (indicating lower trading interest), while the 50-day ($3.35) and 200-day ($2.41) moving averages and the 12‑month range ($0.65–$5.30) provide context for support/resistance levels. Article Title
• Negative Sentiment: Cluster of insider selling on March 16 — CEO George Magrath sold 24,438 shares (~$127k at ~$5.21), Ashwath Jayagopal sold 3,719 shares, COO Joseph K. Schachle sold 3,719 shares, and Amy Zaremba Rabourn sold 2,816 shares. These disclosures (filed with the SEC) represent modest reductions in insider stakes and are likely a principal driver of near-term downward pressure on the stock. Insider Trades CEO Form 4

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.